Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52- week treatment period. Method...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2023-01-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/effectiveness-of-risankizumab-in-the-treatment-of-palmoplantar-psoriasis-a-52-week-italian-real-life-experience/ |
| _version_ | 1797847651329245184 |
|---|---|
| author | Giacomo Caldarola Arianna Zangrilli Gerardo Palmisano Mauro Bavetta Gaia Moretta Gianluca Pagnanelli Vincenzo Panasiti Luca Bianchi Clara De Simone Ketty Peris |
| author_facet | Giacomo Caldarola Arianna Zangrilli Gerardo Palmisano Mauro Bavetta Gaia Moretta Gianluca Pagnanelli Vincenzo Panasiti Luca Bianchi Clara De Simone Ketty Peris |
| author_sort | Giacomo Caldarola |
| collection | DOAJ |
| description | Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52- week treatment period.
Methods: We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity.
Results: Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16.
Conclusion: Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP. |
| first_indexed | 2024-04-09T18:14:53Z |
| format | Article |
| id | doaj.art-b8d9560021404da4b24fe3784f84baca |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-04-09T18:14:53Z |
| publishDate | 2023-01-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-b8d9560021404da4b24fe3784f84baca2023-04-13T05:00:05ZengBioExcel Publishing LtdDrugs in Context1740-43982023-01-01121510.7573/dic.2023-1-8Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experienceGiacomo CaldarolaArianna ZangrilliGerardo PalmisanoMauro BavettaGaia MorettaGianluca PagnanelliVincenzo PanasitiLuca BianchiClara De SimoneKetty PerisBackground: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52- week treatment period. Methods: We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity. Results: Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16. Conclusion: Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.https://www.drugsincontext.com/effectiveness-of-risankizumab-in-the-treatment-of-palmoplantar-psoriasis-a-52-week-italian-real-life-experience/efficacyil-23psoriasisreal-liferisankizumabsafety |
| spellingShingle | Giacomo Caldarola Arianna Zangrilli Gerardo Palmisano Mauro Bavetta Gaia Moretta Gianluca Pagnanelli Vincenzo Panasiti Luca Bianchi Clara De Simone Ketty Peris Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience Drugs in Context efficacy il-23 psoriasis real-life risankizumab safety |
| title | Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience |
| title_full | Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience |
| title_fullStr | Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience |
| title_full_unstemmed | Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience |
| title_short | Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience |
| title_sort | effectiveness of risankizumab in the treatment of palmoplantar psoriasis a 52 week italian real life experience |
| topic | efficacy il-23 psoriasis real-life risankizumab safety |
| url | https://www.drugsincontext.com/effectiveness-of-risankizumab-in-the-treatment-of-palmoplantar-psoriasis-a-52-week-italian-real-life-experience/ |
| work_keys_str_mv | AT giacomocaldarola effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT ariannazangrilli effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT gerardopalmisano effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT maurobavetta effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT gaiamoretta effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT gianlucapagnanelli effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT vincenzopanasiti effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT lucabianchi effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT claradesimone effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience AT kettyperis effectivenessofrisankizumabinthetreatmentofpalmoplantarpsoriasisa52weekitalianreallifeexperience |